Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis

Bibliography

• Patel S, Veale D, Fitzgerald O, McHugh NJ. Psoriatic arthritis–emerging concepts. Rheumatology (Oxford) 2001;10(3):243-6
   Web of Science ®Google Scholar
• Soderlin MK, Borjesson O, Kautiainen H, Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002;61(10):911-15
   PubMed Web of Science ®Google Scholar
• Savolainen E, Kaipiainen-Seppanen O, Kroger L, Luosujarvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003;30(11):2460-8
   PubMed Web of Science ®Google Scholar
• Bruce IN. Psoriatic arthritis: clinical features. In: Hochberg MC, Silman JS, Smolen ME, Weinblatt M, Weisman M, editors, Rheumatology. 3rd edition. Mosby, Philadelphia; 2003. p. 1241-52
   Google Scholar
• Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53(8):511-18
   PubMed Web of Science ®Google Scholar
• Gladman DD. Psoriatic arthritis. Baillieres Clin Rheumatol 1995;9(2):319-29
   PubMed Web of Science ®Google Scholar
• Shbeeb M, Uramoto KM, Gibson LE, The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27(5):1247-50
   PubMed Web of Science ®Google Scholar
• Galadari H, Fuchs B, Lebwohl M. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003;42(3):231-7
   PubMed Web of Science ®Google Scholar
• Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol 2003;49(2 Suppl):S125-32
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45(2):151-8
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation benchmark survey on psoriasis and psoriatic arthritis: summary of top-line results. National Psoriasis Foundation, 2009. Available from: http://www.psoriasis.org/news/press/2002/20020515_lifesurvey.php [Last accessed 27 March 2010]
   Google Scholar
• Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54(4):685-704
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150-7
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52(4):1227-36
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34(5):1040-50
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(10):3279-89
   PubMed Web of Science ®Google Scholar
• Ettehadi P, Greaves MW, Wallach D, Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96(1):146-51
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor – a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34(5):1040-50
   PubMed Web of Science ®Google Scholar
• Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res Ther 2009;11:112
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, Efficacy and safety of anti-TNF agents in psoriatic arthritis: an observational study from the BSR biologics register. Rheumatology (Oxford) 2010;49:697-705
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67(3):364-9
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Kaufmann C, Rodevand E, The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66(8):1038-42
   PubMed Web of Science ®Google Scholar
• Fransen J, Antoni C, Mease PJ, Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 2006;65(10):1373-8
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45(12):1558-65
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, Improvements in quality of life and functional status of psoriatic arthritis patients with anti-TNF therapies. Arthritis Care Res 2010;62(3):345-53
   Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66(2):163-8
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32(1):40-66
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Nordvag BY, Mikkelsen K, The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52(8):2506-12
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007;24(3):239-54
   PubMed Web of Science ®Google Scholar
• de VK, Lories RJ. Update in treatment options for psoriatic arthritis. Expert Rev Clin Immunol 2009;5(6):779-88
   PubMed Web of Science ®Google Scholar
• Seki E, Matsushita I, Sugiyama E, Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 2009;28(4):453-60
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50(5):1400-11
   PubMed Web of Science ®Google Scholar
• Montecucco C. Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies. Drugs 2006;66(14):1783-95
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56(2):476-88
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M, Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52(4):1020-30
   PubMed Web of Science ®Google Scholar
• den Broeder AA, Joosten LA, Saxne T, Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61(4):311-18
   PubMed Web of Science ®Google Scholar
• Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007;8(3):143-55
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Van Der HD, Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35(5):869-76
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8(3):R72
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59(2):234-40
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, Persistence with anti-TNF therapies in patients with psoriatic arthritis: observational study from the BSR biologics register. Arthritis Res Ther 2009;11(2):R52
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8(1):R29
   PubMed Web of Science ®Google Scholar
• Genevay S, Finckh A, Ciurea A, Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;57(4):679-85
   PubMed Web of Science ®Google Scholar
• Filippini M, Bazzani C, Favalli EG, Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010;38(2-3):90-6
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2010. [Epub ahead of print]
   Google Scholar
• Filippini M, Bazzani C, Zingarelli S, Anti-TNFalpha agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients. Reumatismo 2008;60(1):41-9
   PubMedGoogle Scholar
• Kyle S, Chandler D, Griffiths CE, Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005;44(3):390-7
   PubMed Web of Science ®Google Scholar
• Bateman J, Cardy CM, Khan SY, Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy. Clin Exp Rheumatol 2009;27(6):935-9
   PubMed Web of Science ®Google Scholar
• Leeb BF, Bottcher E, Brezinschek HP, The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol 2010;29(2):167-74
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68(9):1387-94
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64
   PubMed Web of Science ®Google Scholar
• Pham T, Fautrel B, Dernis E, Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007;74(6):638-46
   PubMed Web of Science ®Google Scholar
• Pham T, Guillemin F, Claudepierre P, TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 2006;73(5):547-53
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006;33(7):1228-30
   PubMed Web of Science ®Google Scholar
• Salvarani C, Olivieri I, Cantini F, Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society. Reumatismo 2004;56(3):133-4
   PubMedGoogle Scholar
• McKenna SP, Doward LC, Whalley D, Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63(2):162-9
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Strand V, Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34(5):1167-70
   PubMed Web of Science ®Google Scholar
• Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004;16(4):350-6
   PubMed Web of Science ®Google Scholar
• Gladman DD, Strand V, Mease PJ, OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005;64(Suppl 2):ii115-16
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR, Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20(3):557-60
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48-53
   PubMed Web of Science ®Google Scholar
• Gladman DD, Rahman P, Krueger GG, Clinical and genetic registries in psoriatic disease. J Rheumatol 2008;35(7):1458-63
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis 2005;64(Suppl II):ii103-5
   PubMedGoogle Scholar
• Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58(6):1566-75
   PubMed Web of Science ®Google Scholar
• De VS, Zaja F, Sacco S, Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46(8):2029-33
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. MabThera 100 and 500 mg (10 mg/ml) concentrate for solution for infusion. Electronic Medicines Compendium, 2008. Available from: http://emc.medicines.org.uk/industry/default.asp [Last accessed 01 March 2010]
   Google Scholar
• Vieira FJ, Callado MR, Vieira WP. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol Int 2010;30(6):849-50
   PubMed Web of Science ®Google Scholar
• Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010;6(2):189-95
   PubMed Web of Science ®Google Scholar
• Hushaw LL, Sawaqed R, Sweis G, Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010;6:143-52
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Kondo M, Harada H, Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20(4):343-52
   PubMed Web of Science ®Google Scholar